Glucagon-like peptide-1 receptor agonists inhibit hepatic stellate cell activation by blocking the p38 MAPK signaling pathway

L.K. Wu¹, Y.C. Liu¹, L.L. Shi¹ and K.D. Lu²

¹The Second Clinical College, Zhejiang TCM University, Gongshu District, Hangzhou, China
²The First Clinical College, Zhejiang TCM University, Shangcheng District, Hangzhou, China

Corresponding author: K.D. Lu
E-mail: ltaohong@163.com

Received August 10, 2015
Accepted October 7, 2015
Published December 29, 2015
DOI http://dx.doi.org/10.4238/2015.December.29.17

ABSTRACT. We investigated the effects of glucagon-like peptide-1 receptor (GLP-1R) agonists on p38 mitogen-activated protein kinase (MAPK) signaling during inhibition of hepatic stellate cell (HSC) activity. Human HSCs were cultured and morphologically identified. HSC samples were collected and randomly divided into three groups (N = 20 samples per group): a control group treated with high glucose (final concentration 25 mM); a GLP-1R agonist group treated with liraglutide (final concentration 5 mM); and a p38-blocked group treated with the p38 MAPK inhibitor SB203580 (final concentration 14 µM). All cells were cultured for 120 h followed by detection of phosphorylated p38 MAPK (p-p38 MAPK) and α-smooth muscle actin (α-SMA, a measure of HSC activation) by western blot. p-p38 MAPK and α-SMA expression levels were both significantly lower in HSCs in the GLP-1R agonist and p38-blocked groups compared with the control group (all P < 0.01). GLP-1R agonists may inhibit the activation of HSCs by blocking the p38 MAPK signaling pathway.

Key words: Hepatic stellate cell; α-smooth muscle actin; p38 mitogen-activated protein kinase signaling pathway; Glucagon-like peptide-1 receptor agonist
INTRODUCTION

Fatty liver disease specific to type 2 diabetes is called diabetic type 2-associated fatty liver (DFL), and it is a common complication of type 2 diabetes. Patients with diabetes have a high incidence of liver fibrosis caused by DFL and this has become a major cause of liver cirrhosis in China. The main clinical treatment for diabetes and DFL involves regulating blood sugar and lipids, but there is currently no satisfactory treatment for liver fibrosis caused by diabetes. GLP-1 is an incretin secreted from liver cells in the ileum and colon, which can stimulate pancreatic beta cells to secrete insulin at high blood glucose levels. GLP-1R agonists such as liraglutide and exenatide, which directly target GLP-1Rs, have recently received attention for the treatment of type 2 diabetes. Furthermore, interest in DPP-4 inhibitors such as sitagliptin and vildagliptin, which target GLP-1Rs indirectly, has also increased because of their convenience as oral formulations. These drugs can exert direct or indirect effects on pancreatic beta cells, stimulating them to secrete insulin through downstream signal transduction. They can also improve the function and inhibit apoptosis of pancreatic beta cells; therefore, these drugs are of interest for the treatment of type 2 diabetes.

Glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors are antidiabetic agents that directly or indirectly target the GLP-1R, and have recently been widely used in clinical settings. GLP-1Rs are expressed not only by pancreatic beta cells but also in other tissues such as heart, kidney, and lung. It was recently found that GLP-1 demonstrated antagonistic effects on fibrosis in multiple organs, including the liver. The key step in liver fibrosis involves hepatic stellate cell (HSC) activation leading to excessive deposition of extracellular matrix, suggesting that the antagonistic effect of GLP-1 on hepatic fibrosis may involve the signal transduction pathways that regulate HSC activation. Alpha-smooth muscle actin (α-SMA) protein expression levels are a measure of HSC activation. Given the close relationship between the p38 mitogen-activated protein kinase (MAPK) signaling pathway and the activation of HSCs, we focused on the role of this pathway in the mechanism of GLP-1R agonist-mediated inhibition of HSC activation.

MATERIAL AND METHODS

Cell lines and reagents

The HSC line LI-90 was obtained from the Experimental Animal Center of Sun Yat-sen University (Guangzhou, China). L-Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Gibco (USA). Fetal calf serum was purchased from Harry Bio-Engineering Co. Ltd. (Chengdu, China). The p38 MAPK inhibitor SB203580 was purchased from New England Biolabs (USA). Primary antibodies and the corresponding species labeled secondary antibodies for α-SMA, phospho (p)-p38 MAPK and GAPDH were purchased from Boster Bio-Engineering Co. Ltd. (Wuhan, China). The enhanced chemiluminescence kit was purchased from KGI Bio-Technology Development Co. Ltd. (Nanjing, China). Liraglutide was purchased from Novo Nordisk (Denmark).

Grouping

HSC samples were collected and randomly divided into three groups (N = 20 for each group): a control group treated with high glucose (final concentration 25 mM); a GLP-1R agonist group treated with liraglutide (final concentration 5 mM); and a p38-blocked group, treated with the p38 MAPK blocking agent SB203580 (final concentration 14 µM). All cells were cultured for 120 h and then used in subsequent experiments.
Experimental methods

HSC culture

After recovery, HSCs were seeded in 2.5-mL plastic culture flasks. HSCs were routinely cultured in a 5% CO₂ humidified incubator at 37°C. The culture medium was L-DMEM containing 10% (v/v) fetal bovine serum (Gibco, USA) and the media were changed every 3 days.

Analysis of HSC morphology

HSCs were examined under an inverted microscope, and appeared flat with large cell bodies and well-developed stress fibers. They also lacked cytoplasmic lipid droplets.

Extraction and quantification of sample protein

HSC lysates were collected using a buffer containing 8 M urea, 4% CHAPS, 1% tributyl phosphate (TBP), 0.2% BioLyte, and 0.001% bromophenol blue. After an ice bath with intermittent ultrasound and 15,000 g high-speed centrifugation at 4°C, cell supernatants were obtained, and the protein concentration was estimated using a Bradford assay.

Detection of α-SMA or p-p38 MAPK expression in human HSCs by western blot

Proteins were separated using 10% SDS-PAGE with Tris-glycine running buffer. After electrophoresis, the protein bands were transferred to 350 mA for 1 h onto a PVDF membrane. The membrane was then rinsed with TBS for 10 min. The PVDF membrane was incubated for 1 h at room temperature in blocking solution (5% skim milk in 1X TBS-T). The membranes were rinsed in 1X TBS-T three times for 5 min. The PVDF membrane was incubated at 4°C overnight in the α-SMA or p-p38 MAPK primary antibody diluted in blocking solution (1:100 or 1:1000, respectively). The next day, the membrane was rinsed three times for 5 min in 1X TBS-T. The PVDF membrane was incubated at 37°C for 1 h in horseradish peroxidase-conjugated secondary antibodies diluted in blocking solution (1:3000 for α-SMA and 1:2000 for p-p38 MAPK) while shaking. The membrane was rinsed with 1X TBS-T three times for 5 min and washed once with TBS. The PVDF membrane was visualized using an enhanced chemiluminescence kit. The film was exposed, developed, and fixed, and analyzed by a transilluminator and its software (BD Biosciences, USA). GAPDH was used as an internal reference for semi-quantitative analysis.

Statistical analysis

Statistical analysis was conducted using the SPSS 17.0 software (Chicago, IL, USA). Statistical data were normally distributed. The Student t-test for two independent samples was used for statistical analysis.

RESULTS

Expression of p-p38 MAPK

p-p38 MAPK protein expression levels in each group were detected by western blot using GAPDH as an internal reference (Figure 1).
Figure 1. Expression levels of p-p38 MAPK protein in each group (control, GLP-1R agonist, and p38-blocked) detected by western blot. GAPDH is shown as an internal control. Densitometric analysis is shown in Table 1.

Expression of α-SMA in each treatment group

α-SMA protein expression levels are a measure of HSC activation and their levels in each group were detected by western blot with GAPDH as an internal reference (Figure 2).

Figure 2. Expression levels of α-SMA protein in each group (control, GLP-1R agonist, and p38-blocked) detected by western blot. GAPDH is shown as an internal control. Densitometric analysis is shown in Table 1.

Statistical analysis of experimental data

p-p38 MAPK protein expression levels were significantly lower in the GLP-1R agonist and p38-blocked groups compared with the control group (both P < 0.01; Table 1). Similarly, α-SMA expression levels were also significantly lower in the GLP-1R agonist and p38-blocked groups compared with the control group (both P < 0.01; Table 1). These results demonstrate that p-p38 MAPK and α-SMA expression levels were both significantly reduced by treatment with the GLP-1R agonist liraglutide, suggesting that GLP-1R agonists can inhibit p38 MAPK signaling and HSC activation. α-SMA expression levels were also reduced by the p38 blocker SB203580, suggesting that HSC activation can be inhibited by blocking the p38 MAPK pathway. Overall, these results indicate that GLP-1R agonists may inhibit the activation of HSCs by blocking the p38 MAPK pathway.
GLP-1R and hepatic stellate cell activation

Table 1. Densitometric analysis of α-SMA and p-p38 MAPK expression by using western blot (means ± SD).

<table>
<thead>
<tr>
<th>Group</th>
<th>p-p38 MAPK/GAPDH (%)</th>
<th>α-SMA/GAPDH (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>22.79 ± 3.80</td>
<td>34.61 ± 4.07</td>
</tr>
<tr>
<td>GLP-1R agonist</td>
<td>10.13 ± 4.955*</td>
<td>23.90 ± 6.02*</td>
</tr>
<tr>
<td>p38-blocked</td>
<td>8.66 ± 4.15*</td>
<td>26.49 ± 4.41*</td>
</tr>
</tbody>
</table>

*GLP-1R agonist group compared with control group, P < 0.01; p38-blocked group compared with control group, P < 0.01.

DISCUSSION

In the present study, we found p-p38 MAPK and α-SMA expression levels were both significantly lower in HSCs in the GLP-1R agonist and p38-blocked groups compared with the control group (all P < 0.01). GLP-1R agonists may inhibit the activation of HSCs by blocking the p38 MAPK signaling pathway.

GLP-1Rs are not confined to the pancreas and have recently been shown to be widely expressed throughout the body. GLP-1Rs have been detected in the heart, liver, and thyroid, where they may play many important physiological roles (Gupta et al., 2010; Gier et al., 2012; Monji et al., 2013; Lockie, 2013). In addition to regulating insulin secretion in relation to blood sugar levels, GLP-1 has also been shown to play protective and anti-fibrotic roles in the cardiovascular system. Park et al. (2007) treated 8-week-old male db/db mice with the long-acting GLP-1R agonist liraglutide for 8 weeks and found that the expression of transforming growth factor-β1 and type IV collagen were significantly decreased. Hillman et al. (2012) recently found that GLP-1 levels were significantly reduced in cystic fibrosis patients (P < 0.01) compared with healthy individuals. In an electron microscope study, Tang et al. (2008) observed that the endothelial basement membrane thickness of pulmonary capillaries was significantly decreased following treatment with GLP-1 for 8 weeks in the Otsuka-Long-Evans-Tokushima fatty rat model (P < 0.01). The anti-fibrotic effects of GLP-1 have thus been confirmed. We speculate that the mechanisms responsible for this anti-fibrotic effect are complex and may involve multiple pathways in different organs. Excessive deposition of extracellular matrix as a result of HSC activation is key in the pathology of liver fibrosis (Friedman, 2008a), which is regulated by the balance between HSC activation and apoptosis. Regulation of HSC activation can thus regulate the progress of liver fibrosis, and inhibition of HSC activation is important for halting, or even reversing, liver fibrosis (Baba et al., 2004; Russo et al., 2006; Roderfeld et al., 2006; De Minicis et al., 2007; Friedman, 2008b).

The mechanisms regulating HSC activation are extremely complex. Cell factors and activation products generated from liver cells, Kupffer cells, endothelial cells, and HSCs themselves, as well as environmental stimulation by drugs, can regulate the biological behavior of HSCs through various signaling pathways (Lin and Wang, 2006). The p38 MAPK signaling pathway was recently shown to play an important role in HSC stress, activation, proliferation, apoptosis, phenotypic transdifferentiation, and other physiological and pathological processes (Aouadi et al., 2006; Brown and Sacks, 2008; Kyriakis and Avruch, 2012). External signals can regulate HSC activation through the p38 MAPK signaling pathway and thus regulate hepatic fibrosis. This pathway includes signal transduction cascades that are initiated by extracellular signals and eventually lead to important intracellular biological effects. p-p38 MAPK is formed by the dual phosphorylation of specific threonine and tyrosine residues (Kim and Choi, 2010), after which it is rapidly transferred to the nucleus where it acts on the corresponding target to promote HSC activation (Tahashi et al., 2002).
We previously demonstrated that GLP-1Rs were expressed in human HSCs (Wu et al., 2013), and it is known that GLP-1R stimulation can have an anti-fibrotic effect. We investigated the involvement of the p38 MAPK signaling pathway in fibrosis and demonstrated that the GLP-1R agonist liraglutide could inhibit HSC activation by inhibiting p38-MAPK phosphorylation and consequently the p38 MAPK pathway. These results suggest that both GLP-1R agonists and DPP-4 inhibitors, which act indirectly on GLP-1Rs, could inhibit HSC activation via the p38-MAPK pathway and thus represent potential treatments for liver fibrosis. Further studies are needed to elucidate the mechanisms involved.

Conflicts of interest

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

Research supported by the Zhejiang Provincial Health Science and Technology Program (2013KYA144).

REFERENCES


